The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 1.53%.However, over the last six months, we can see a stronger performance of -27.19%. Over the last 30 days, the price of ABUS has fallen by 0.30%. And in the last five days, it has fallen by -1.48%.
Arbutus Biopharma Corp experienced a rather steady stock market performance. The highest value in the past year was recorded at $4.72 on 09/09/24 and the lowest value was $2.30 on 04/03/24.
52-week price history of ABUS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Arbutus Biopharma Corp’s current trading price is -29.74% away from its 52-week high, while its distance from the 52-week low is 44.35%. The stock’s price range during this period has varied between$2.30 and $4.72. The Arbutus Biopharma Corp’s shares, which operate in the Healthcare, saw a trading volume of around 1.32 million for the day, a figure considerably higher than their average daily volume of 0.88 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Arbutus Biopharma Corp (ABUS) has experienced a quarterly decline of -9.78% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 629.11M and boasts a workforce of 73 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.49, with a change in price of -0.88. Similarly, Arbutus Biopharma Corp recorded 858,879 in trading volume during the last 100 days, posting a change of -20.95%.
ABUS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ABUS stands at 0.06. Similarly, the long-term debt-to-equity ratio is also 0.06.
ABUS Stock Stochastic Average
Arbutus Biopharma Corp’s raw stochastic average for the past 50 days is presently 44.12%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 44.12%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 25.00% and 14.94%, respectively.
